8-K: Inotiv Q1 FY26: DSA Growth Offsets RMS Decline

Inotiv, Inc. reported a slight revenue increase in the first quarter of fiscal 2026, driven by strong growth in its Discovery and Safety Assessment segment, despite a decline in Research Models and Services.

Summary

• Total revenue for Q1 FY 2026 was $120.9 million, a 0.8% increase from $119.9 million in Q1 FY 2025.
• Discovery and Safety Assessment (DSA) revenue grew 12.0% to $48.0 million, while Research Models and Services (RMS) revenue decreased 5.4% to $72.9 million.
• Consolidated net loss for Q1 FY 2026 was $28.4 million, an increase from $27.6 million in Q1 FY 2025.
• Adjusted EBITDA for Q1 FY 2026 was $1.8 million, down from $2.6 million in Q1 FY 2025.
• The DSA segment reported a book-to-bill ratio of 1.16x and a backlog of $145.4 million at December 31, 2025.
• Cash and cash equivalents decreased to $12.7 million at December 31, 2025, from $21.7 million at September 30, 2025.
• Total debt, net of issuance costs, increased to $405.8 million at December 31, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a challenging quarter with declining profitability and cash, despite strong performance in the DSA segment. The overall financial health shows deterioration, overshadowed by ongoing legal and operational costs.

Positives

• Overall revenue increased by 0.8% year-over-year to $120.9 million.
• Discovery and Safety Assessment (DSA) segment revenue increased significantly by 12.0% to $48.0 million.
• DSA net awards grew approximately 27% year-over-year.
• DSA book-to-bill ratio was strong at 1.16x, indicating future revenue potential.
• DSA backlog increased to $145.4 million at December 31, 2025, up from $130.4 million a year prior.
• The company is executing on its U.S. site optimization plan by exiting two leased facilities during Q1 FY 2026.

Negatives

• Consolidated net loss increased to $28.4 million in Q1 FY 2026 from $27.6 million in Q1 FY 2025.
• Operating loss increased to $16.3 million in Q1 FY 2026 from $15.5 million in Q1 FY 2025.
• Adjusted EBITDA decreased to $1.8 million in Q1 FY 2026 from $2.6 million in Q1 FY 2025.
• Research Models and Services (RMS) revenue decreased by 5.4% to $72.9 million, primarily due to lower non-human primate (NHP) volumes sold.
• Cash and cash equivalents declined significantly to $12.7 million at December 31, 2025, from $21.7 million at September 30, 2025.
• Cash used in operating activities increased to $5.4 million in Q1 FY 2026 from $4.5 million in Q1 FY 2025.
• Total debt, net, increased to $405.8 million at December 31, 2025, from $402.1 million at September 30, 2025.

Risks

• Fluctuations in research and development spending by pharmaceutical and biotechnology companies.
• Market and company-specific impacts of non-human primate (NHP) supply and demand matters.
• Compliance with the Resolution Agreement and Plea Agreement, including associated costs and impacts of the compliance plan and monitor.
• Ability to service substantial outstanding indebtedness and comply or regain compliance with financial covenants.
• Current and forecasted cash position and ability to make capital expenditures, fund operations, and satisfy obligations.
• Ability to manage recurring and unusual costs.
• Ability to execute on and realize expected benefits from restructuring and site optimization plans.
• Ability to effectively fill expanded capacity or any future expansion or acquisition initiatives.
• Ability to develop and build infrastructure and teams to manage growth and projects.
• Ability to retain and hire key talent.
• Ability to market services and products under corporate and brand names.
• Ability to develop new services and products.
• Ability to negotiate amendments to the Credit Agreement or obtain waivers related to financial covenants.
• Potential outcome of litigation against the company, including any settlement and amounts accrued or recoverable.
• Ability to maintain effective data protection, privacy and cybersecurity measures and mitigate risks from cyber incidents, including the 2025 Cybersecurity Incident.
• Impact of macroeconomic factors, including tariffs and trade policies.

Future Outlook

The company anticipates continued encouraging demand trends, particularly within its DSA segment, and aims to build durable client relationships and a growing base of recurring business. It also expects to continue advancing strategic initiatives, including site optimization.

Management Comments

• "During the first quarter of fiscal 2026, we continued to execute on our operational and financial priorities, with a sustained focus on client service and margin discipline."
• "Demand trends, particularly within our DSA segment, remained encouraging and reflect the value clients place on our capabilities and partnership approach."
• "Client satisfaction and reliable, on-time delivery of high-quality products and services remain central to our strategy."
• "These results underscore the progress we are making toward building durable client relationships and a growing base of recurring business."

Industry Context

StockSavvy.ai notes that Inotiv's mixed performance reflects broader trends in the contract research organization (CRO) sector, where specialized services like Discovery and Safety Assessment are seeing robust demand, while segments reliant on specific research models, such as non-human primates, face supply chain and volume challenges. The strong DSA book-to-bill ratio suggests a healthy pipeline in a competitive market.

Legal Proceedings

• Ongoing compliance with the Resolution Agreement and Plea Agreement.
• Costs incurred in connection with the 2025 Cybersecurity Incident.
• Potential outcome of litigation against the company.

Stakeholder Impact

• Shareholders: Increased net loss, decreased Adjusted EBITDA, and declining cash position could negatively impact shareholder value. The increase in debt also adds risk.
• Employees: Continued focus on operational priorities and site optimization may lead to further restructuring or changes.
• Customers: Strong DSA segment growth and focus on client satisfaction suggest positive engagement for those services.
• Creditors: Increased debt and declining cash flow raise concerns about the company's ability to service its substantial outstanding indebtedness.

Next Steps

• Continue executing on operational and financial priorities, focusing on client service and margin discipline.
• Advance strategic initiatives, including site optimization.
• Host a conference call on February 9, 2026, at 8:30 am ET to discuss results.

Key Dates

Recommendation

The company reported increased net losses, a decline in Adjusted EBITDA, and a significant reduction in cash and cash equivalents, alongside an increase in total debt. While the DSA segment shows growth, it is not enough to offset the overall financial deterioration and the decline in the RMS segment. The ongoing legal and cybersecurity costs, coupled with the need to service substantial debt, present significant financial headwinds. These factors indicate a worsening financial position, warranting a "sell" recommendation for seasoned investors.

Keywords

Contract Research Organization, Drug Discovery, Drug Development, Preclinical Services, Research Models, Safety Assessment, Biotechnology, Pharmaceutical, CRO, Inotiv, NOTV, Financial Results, Q1 FY26